Objective: Childhood obesity is a growing global epidemic. Recent studies indicate that obesity and related metabolic traits are highly heritable. Increasing evidence suggests that growth hormone (GH) and the insulin-like growth factor-I (IGF-I) axis have important functions in regulating adiposity and insulin sensitivity. Five single-nucleotide polymorphisms (SNPs) at IGF-binding protein-3 (IGFBP3) were genotyped to find their associations with IGF-1 activity level and common clinical metabolic traits. Patients and Methods: We examined the associations of five SNPs at IGFBP3 with serum IGF-I and IGFBP-3 levels, as well as with obesity-related metabolic traits in 981 Hong Kong Chinese adolescents. Factor analysis was used to reduce the intercorrelated variables to five factor scores indicating body composition, blood pressure, IGF-I activity, triglyceride (TG) þ high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) þ low-density lipoprotein cholesterol (LDL-C) factor scores. Results: There was a strong association between the À202A/C polymorphism (rs2854744) and IGF-I activity (P ¼ 1.2 Â 10 À6 ) and TC þ LDL-C factor scores (P ¼ 0.0085), corrected for age and sex. The C allele was associated with decreased IGFBP-3 levels (P ¼ 1.21 Â 10 À13 ), increased IGF-I/IGFBP-3 molar ratio (P ¼ 5.22 Â 10 À6 ) and decreased LDL-C (P ¼ 0.020). There was also a significant association between a G/A polymorphism at the 3 0 flanking sequence (rs13223993) of the IGFBP3 gene and the TG þ HDL-C factor score (P ¼ 0.0013). The minor A allele carriers of rs13223993 had a lower HDL-C (P ¼ 0.0067) level and a tendency toward a high TG level. Haplotype analysis did not increase the significance of associations between single SNPs and phenotypes. Conclusion: Our results support the function of IGFBP3 gene polymorphisms in modulating IGF-I activity and lipid levels in adolescents. Given the prognostic significance of IGF-I, IGFBPs and lipids on risk of diabetes, obesity and cancer, long-term studies are required to clarify the clinical meaning of these findings.
Introduction
Childhood obesity has reached epidemic levels globally. The prevalence of childhood obesity has tripled between 1980 and 2000 in the USA and doubled between 1985 and 1995 in Australia. 1 Similar rising trends are evident in China, Canada, the UK, Germany, France and Finland. 1 Our group has reported a prevalence of abdominal obesity (9%) in a territory-wide school survey of 2000 adolescents in Hong Kong. 2 Obesity is likely to track from childhood into adulthood, 3 leading to an early onset of type 2 diabetes and cardiorenal complications. 4 We, 5 along with others, 6 have reported high heritability (h 2 40 .60) of obesity and related quantitative traits including skinfold thickness, waist circumference and fat distribution, supporting the important functions of genetics and/or shared environment in modulating adiposity.
Our group has also reported a low growth hormone (GH) level in young Chinese patients with type 2 diabetic 7 and low insulin-like growth factor-I (IGF-I) levels in middle-aged men with metabolic syndrome, 8 compared with control subjects, as well as their associations with obesity and related traits. Other investigators have shown the beneficial effects of GH therapy in reducing adiposity and improving metabolic control in patients with type 2 diabetes. 9, 10 Although much of the growth-promoting effects of GH are mediated by IGF-I synthesized by the liver, IGF-I also binds weakly to insulin receptors, and thus may give rise to multiple effects on intermediary metabolism. In keeping with this notion, GH decreases body fat mass by stimulating lipolysis, 11 whereas IGF-I exerts lipogenic effects similar to those of insulin and inhibits GH actions by negative feedback. 12 Moreover, the effects of IGF-I are tightly regulated at various tissue levels by different binding proteins. Circulating IGF-I is stabilized by forming a ternary complex with IGF-binding protein-3 (IGFBP-3) and the acid-labile subunit, 13 which is also the principal carrier protein during postnatal life. 14 Thus, in the assessment of activity of the GH/IGF-I axis, because of the oscillating nature and diurnal variation of GH secretion, measurement of IGF-I and IGFBP-3 may be more indicative of GH/IGF-I axis activity.
There are several lines of evidence supporting the dysregulation of IGF-I and their binding proteins including IGFBP-3 in diabetes, obesity, insulin resistance, cardiovascular diseases and cancers. [15] [16] [17] Given the large number of factors that confound obesity, including age, medications and comorbidities, a study of the relationship between components of the GH/IGF-I axis and obesity-related traits may be more informative in adolescents than in adults. With the onset of puberty, adolescents exhibit an increased activity of the GH/IGF-I axis, which then stimulates somatic growth in various tissues, especially in the presence of exercise and high protein intake. 18 To further understand the genetic contribution to the IGF1-IGFBP axis, we explored the associations of five tagging single-nucleotide polymorphisms (SNPs) at IGFBP3 with obesity-related traits, as well as with IGF-I and IGFBP-3 levels, in 981 Hong Kong Chinese adolescents.
Patients and methods

Subjects
The study design and phenotypes of these subjects, including anthropometric measurements, cardiovascular risks, as well as IGF-I and IGFBP-3 levels, have been reported. 19, 20 In brief, 53 schools were randomly selected from 477 secondary schools in Hong Kong using a computer-generated coding system. Of these 53 schools, 14 schools participated in the survey with consent from school principals. Six classes, one from each grade (form 1 to form 6, equivalent to grade 7 to grade 12 in the USA), were randomly selected from each school. Only adolescents of Chinese ethnicity were recruited for assessment. Among the 2115 subjects recruited, 981 adolescents were randomly selected for this study. The clinical and biochemical characteristics of this subset of adolescents were comparable with those of the main cohort ( Table 1) . The study was approved by the clinical research ethics committee of the Chinese University of Hong Kong. Informed consent was obtained from all participants, together with their parents' informed and written consent.
Clinical and laboratory assessments
After an overnight fast of at least 8 h, anthropometric measurements and blood samples were collected from each participant during field study at the school by a team of trained research nurses and assistants. 19, 20 Fasting blood samples were assayed for fasting plasma glucose (FPG), fasting insulin (FINS), lipids, triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and calculated low-density lipoprotein cholesterol (LDL-C). Sera were also assayed for IGF-I and IGFBP-3 by an automated chemiluminescent assay system (IMMULITE 2000; Diagnostic Products Corp., Los Angeles, CA, USA). The percentage of body fat (%BF) was determined by bioelectrical impedance Sample size estimation Considering a marker allele in linkage disequilibrium (r 2 ) of 0.8 to a quantitative trait locus (QTL), the sample sizes required to attain 80% power at an alpha level of 0.05 are 389 and 781, respectively, if the QTL accounts for 2 and 1% of the total trait variance under an additive model, as estimated by the Genetic Power Calculator. 22 We genotyped a total of 981 random samples from the adolescent cohort to detect at least 1% of trait variance explained by the marker allele. Genotyping DNA was extracted from buffy coat by the standard phenol/ chloroform method. All SNPs were genotyped using primer extension of multiplex products with detection by MALDI-TOF mass spectroscopy on a Sequenom MassARRAY platform (San Diego, CA, USA 
SNP tagging and prioritization
Statistical analyses
Continuous data were expressed as mean ± standard deviation (s.d.) or as geometric mean (95% confidence interval (CI)), and were logarithmically transformed if necessary. All statistical tests were performed using SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA), unless otherwise specified.
Factor analysis was performed to reduce interrelated variables into fewer components before comparisons with genotypes. Thirteen variables, including body mass index (BMI), waist circumference (WC), hip circumference (HC), systolic and diastolic blood pressure (SBP and DBP), %BF, TC, TG, HDL-C, LDL-C, HOMA-IR, IGF-I and IGFBP-3, were chosen for analysis. These variables were first standardized by multiple regression analysis with adjustment for age and sex. Factor extraction was conducted by the method of principal components to retain components with eigenvalues 41. (The eigenvalue for a given factor measures the variance in all the variables that are accounted for by that factor; eigenvalue 41 indicates that the given factor can account for variance in more than one variable so that it is effective.) Both the orthogonal (Varimax) and oblique (Promax) rotation methods gave similar results and thus the former method was used in this study. Conventionally, variables that have a factor loading 40.4 (or less than À0.4) with a particular factor were considered to be its major constituents. Each factor was interpreted according to the variables that were its major constituents. Factor scores were then generated for all subjects, which are linear combinations of the original variables representing the predicted value of a given factor for an individual.
The quantitative traits and factor scores among carriers of different genotypes were compared using analysis of variance. Analyses were performed under additive, dominant and recessive models. For quantitative traits, multivariate linear regression analysis was used to assess the significance of covariates and was adjusted for these confounders (that is, age and sex) in the genotype-phenotype association. The adjusted percentage of the phenotypic variance explained by each genotype was estimated by subtracting the adjusted r 2 value for a model that includes the genotype from the r 2 for a model that excludes it. Differences of phenotypes among haplotypes with frequencies 41% were compared by PLINK (http://pngu.mgh.harvard.edu/purcell/plink/; Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA) , 24 using standardized variables adjusted for age and sex. An uncorrected P-value o0.05 (two-tailed) was considered to be nominally significant. Empirical P-values for multiple allelic tests were also obtained by 10 000 permutations of phenotype labels implemented in PLINK.
Results
Factor analysis of metabolic and hormonal traits Factor analysis of data from these 981 subjects revealed five factors with eigenvalues 41, accounting for 79.8% of the variance in the original variables. The first factor was strongly correlated with BMI, WC, HC, %BF and HOMA-IR; the second factor was strongly correlated with TC and LDL-C; the third factor was strongly correlated with SBP and DBP; the fourth factor was strongly correlated with IGF-I and IGFBP-3; and the fifth factor was strongly correlated with TG
and HDL-C. Thus, these five factors were interpreted as representing body composition, the TC þ LDL-C factor score, BP, IGF-I activity and the TG þ HDL-C factor score. The general pattern of correlation and factor loading results is shown in Supplementary Tables 1 and 2 .
IGFBP3 polymorphisms and factor scores Figure 2 summarizes the association results of IGFBP3 polymorphisms with various factor scores. We observed significant associations of several SNPs with TC þ LDL-C and TG þ HDL-C factor scores, as well as with IGF-I activity factors (P ¼ 8.06 Â 10 À7 to 0.023). We further examined the association of respective SNPs with individual traits.
IGFBP3 polymorphisms and IGF-1 activity
There was a strong association between the À202A/C polymorphism (rs2854744) and the IGF-I activity factor score, accounting for 2.8% of the variance (P ¼ 1. IGFBP3, lipid and hormonal parameters in adolescents JLY Mong et al Table 2 ). The association remained significant after correction for multiple testings by permutation (empirical Po10
À4
). Each copy of the C allele of À202A/C was associated with a decreased IGFBP-3 level (P ¼ 1.21 Â 10 À13 )
and an increased IGF-I/IGFBP-3 ratio (P ¼ 5.22 Â 10
À6
), explaining 6.3 and 2% of their respective variance.
Two additional SNPs, rs3110697 at the third intron and rs2453839 at the fourth intron, showed strong associations with the IGF-I activity factor score (P ¼ 8.06 Â 10 À7 and 1.1 Â 10
À5
, respectively). The associations remained significant after correction for multiple testings (empirical Po10
À4
). However, the significance decreased when controlled for À202A/C (P ¼ 0.010 and 0.487, respectively), indicating that the associations of these two SNPs were probably because of their linkage disequilibrium with À202A/C.
IGFBP3 and lipid measurements
There were also significant associations between À202A/C and the TC þ LDL-C factor score with an explained variance (r 2 ) of 0.6% (P ¼ 0.0085). This remained significant after correction for multiple testings (empirical P ¼ 0.031). The C allele was associated with reduced TC, LDL-C and non-HDL-C (P ¼ 0.0056-0.029).
In addition, we found significant association of a G/A polymorphism at the 3 0 flanking sequence (rs13223993) with the TG þ HDL-C factor score (P ¼ 0.0013; Table 3 ), which remained significant after correction for multiple testings by permutation (empirical P ¼ 0.0062). The association of rs13223993 remained significant even when controlled for rs2453839, rs3110697 and À202A/C (P ¼ 0.0044), indicating that its effect was independent of other SNPs within the gene. Nevertheless, significant association was found only for reduced HDL-C, although there was a trend of association with increased TG under the recessive model for this SNP. Carriers of the minor A allele had low HDL-C (P ¼ 0.0067) and high TG levels, reaching significance for HDL-C. There was no significant association between rs13223993 and the IGF-1 activity factor.
Phenotype associations of IGFBP3 haplotypes
Statistical reconstruction of haplotypes comprising rs13223993 and À202A/C at the IGFBP3 gene identified four common haplotypes of 41% frequency. Haplotype analysis revealed similar results compared with single marker associations (Supplementary Table 3 ).
Discussion
In agreement with previous reports in adults, 23 we confirmed the strong association of the À202A/C polymorphism of the IGFBP3 gene with the IGF-I activity factor comprising IGFBP-3 and IGF-I. In this relatively large cohort of adolescents, C allele carriers of the À202A/C gene polymorphism had a lower IGFBP-3 level, a higher IGF-I/IGFBP-3 IGFBP3, lipid and hormonal parameters in adolescents JLY Mong et al ratio and lower TC and LDL-C levels than did A allele carriers. In addition, carriers of the minor A allele of rs13223993 had a lower HDL-C level and tended to have a higher TG level than did G carriers. This SNP was also in close linkage with other SNPs of the nearby IGFBP1 gene. Although we were not able to confirm our original hypothesis regarding the function of these SNPs on obesity-related traits, our data indicate the importance of genetic influence on IGF-I activity and lipid metabolism in these adolescents with few confounding factors. The GH/IGF-I axis is essential for regulating somatic growth and intermediary metabolism. GH promotes protein synthesis and tissue growth and has potent lipolytic effects to mobilize energy stores and reduce body fat. 11 On the other hand, IGF-I exerts insulinomimetic effects by promoting energy storage and lipogenesis. It is noteworthy that the activity of IGF-I at a cellular level is tightly regulated by its binding proteins, especially IGFBP-3. 12, 14 The latter is the main binding protein that carries IGF-I in circulation and directs it to target tissues. In addition, IGFBP-3 protects IGF-I from proteolytic degradation and regulates the binding of IGF-I to its receptor, 14 whereas free IGF-I levels exert a negative feedback on GH secretion. 12 Although our group has reported the associations of low GH 7 and IGF-I 8 with diabetes and metabolic syndrome in adults, we were unable to show similar genotype-phenotype associations in this adolescent cohort. Such a discrepancy may be because of the marked differences in age among these cohorts.
Other studies have examined the associations of IGF-I and IGFBP-3 with cancer susceptibility. Experimental evidence indicates that IGF-I has antiapoptotic and mitogenic actions that promote tumor growth, whereas IGFBP-3 acts as a sequestering agent for IGF-I to protect against cancer development. 25, 26 In humans, higher circulating IGF-I and lower IGFBP-3 levels are associated with increased cancer risks. 27 In this study, C allele carriers of the -202A/C polymorphism had lower IGFBP-3 levels and a higher IGF-I/IGFBP-3 molar ratio than did A carriers. It is noteworthy that other workers have also reported a risk association of the -202A/C polymorphism with breast and prostate cancers. 23 Given the young age of our subjects, the clinical significance of our findings can only be clarified by prospective studies. However, in keeping with the risk association of cancer with the À202A/C polymorphism, C allele carriers of À202A/C also had reduced levels of TC and LDL-C. Both GH and IGF-I can stimulate LDL-C catabolism 28 and can inhibit lipoprotein lipase activity. 29 To this end, there are emerging data showing the risk association between low LDL-C level and cancer risks. 30 More recently, functional studies on IGFBP3 regulatory regions revealed a methylationdependent binding site for the upstream stimulating factor (USF) located within the haplotype at -202A/C and À185T/C polymorphisms, which was found to influence the basal and insulin-stimulated transcription activity of the IGFBP3 promoter in human leukocytes. 31 In this respect, USF is one of the candidate genes for familial dyslipidemia 32 and type 2 diabetes. 33 Taken together, our findings point to a genetic influence on lipid metabolism through IGF-I activity, which may influence the future risk of cancers. Among the SNPs examined in this cohort, the A allele of rs13223993, an SNP located at the 3 0 flanking sequence of IGFBP3, was associated with low HDL-C and high TG levels reaching significance for HDL-C. It is noteworthy that rs13223993 has a strong linkage disequilibrium with some of the SNPs in the adjacent IGFBP1 gene. In this respect, although IGFBP-1 constitutes only a small percentage of the total pool of circulating IGFBPs, it is considered to be the principal acute regulator of IGF-I activity. The activity of IGFBP-1 is downregulated by insulin and upregulated in catabolic states and by other glucoregulatory hormones and cytokines. 34, 35 However, current literature on the clinical significance of IGFBP-1 remains conflicting. Although some studies have reported low IGFBP-1 levels in subjects with obesity, hyperinsulinemia, 36 impaired glucose tolerance and cardiovascular risks, 37,38 a high IGFBP-1 has been shown to be predictive of cardiovascular mortality and morbidity in IGFBP3, lipid and hormonal parameters in adolescents JLY Mong et al type 2 diabetes in long-term studies. 15 Irrespective of these findings, our results point to complex interactions among the regulatory components of the GH/IGF-I axis at a genetic level, which in turn may influence the risk of diabetes, obesity and possibly cancers. To this end, several studies have also reported risk associations of low IGF-I and high IGFBP-3 with cardiovascular disease. 39, 40 In conclusion, in Chinese adolescents, 2-6% of the variance of IGF-I and IGFBP-3 levels was explained by a single SNP (À202 A/C) of the IGFBP3 gene. Subjects carrying the minor C allele had low IGFBP-3, a high IGF-I/IGFBP-3 ratio and low LDL-C levels. In addition, we observed a strong association of another SNP (rs13223993) with HDL-C level. Given the growing body of knowledge regarding the function of the GH/IGF-I/IGFBP axis in obesity, cardiometabolic risk and cancers, our findings call for longterm and functional studies to determine their clinical significance.
